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Abstract
Mutations of UDP-N-acetyl-alpha-D-galactosamine polypeptide N-acetyl galactosaminyl transferase 3 (GALNT3) result in
familial tumoural calcinosis (FTC) and the hyperostosis-hyperphosphataemia syndrome (HHS), which are autosomal
recessive disorders characterised by soft-tissue calcification and hyperphosphataemia. To facilitate in vivo studies of these
heritable disorders of phosphate homeostasis, we embarked on establishing a mouse model by assessing progeny of mice
treated with the chemical mutagen N-ethyl-N-nitrosourea (ENU), and identified a mutant mouse, TCAL, with autosomal
recessive inheritance of ectopic calcification, which involved multiple tissues, and hyperphosphataemia; the phenotype was
designated TCAL and the locus, Tcal. TCAL males were infertile with loss of Sertoli cells and spermatozoa, and increased
testicular apoptosis. Genetic mapping localized Tcal to chromosome 2 (62.64–71.11 Mb) which contained the Galnt3. DNA
sequence analysis identified a Galnt3 missense mutation (Trp589Arg) in TCAL mice. Transient transfection of wild-type and
mutant Galnt3-enhanced green fluorescent protein (EGFP) constructs in COS-7 cells revealed endoplasmic reticulum
retention of the Trp589Arg mutant and Western blot analysis of kidney homogenates demonstrated defective glycosylation
of Galnt3 in Tcal/Tcal mice. Tcal/Tcal mice had normal plasma calcium and parathyroid hormone concentrations; decreased
alkaline phosphatase activity and intact Fgf23 concentrations; and elevation of circulating 1,25-dihydroxyvitamin D.
Quantitative reverse transcriptase-PCR (qRT-PCR) revealed that Tcal/Tcal mice had increased expression of Galnt3 and Fgf23
in bone, but that renal expression of Klotho, 25-hydroxyvitamin D-1a-hydroxylase (Cyp27b1), and the sodium-phosphate co-
transporters type-IIa and -IIc was similar to that in wild-type mice. Thus, TCAL mice have the phenotypic features of FTC and
HHS, and provide a model for these disorders of phosphate metabolism.
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Introduction
Tumoural Calcinosis (TC) is an autosomal recessive metabolic
disorder which is characterized by progressive deposition of
calcium phosphate crystals in peri-articular skin and soft tissues
that often result in painful skin ulcerations, and secondary
infection of skin and bone [1,2]. Patients with TC may also have
dental abnormalities, retinal angiomatoid streaks and vascular
calcification [3]. The biochemical hallmark of TC is hyperpho-
sphataemia which is caused by increased renal tubular reabsorp-
tion of phosphate [4]. Patients with TC may also have elevated or
inappropriately normal plasma concentrations of 1,25-dihydrox-
yvitamin D, although circulating parathyroid hormone (PTH) and
calcium concentrations are normal [2], and normal or elevated
alkaline phosphatase activity [5]. TC and its familial (FTC) form
may be caused by mutations of either the UDP-N-acetyl-alpha-D-
galactosamine polypeptide N-acetyl galactosaminyl transferase 3
(GALNT3) [2,6–10], fibroblast growth factor 23 (FGF23) [1,10–12],
or KLOTHO (KL) [13] genes. Thus, a total of at least 25 GALNT3
homozygous mutations consisting of 10 missense [3,14–19], 6
nonsense [6,8,9,20,21] and 9 frameshift/deletion [5–8,16,17,22–
25], (Fig. 1 and Table 1) have been reported in patients with FTC
and the hyperostosis-hyperphosphataemia syndrome (HHS),
which are allelic variants [2]; 3 homozygous missense FGF23
mutations (Ser71Gly, Met96Thr and Ser129Phe) have been
reported in patients with TC [1,11,12]; and one homozygous
missense KLOTHO mutation (His193Arg) [13] has also been
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reported in patients with TC. Moreover, GALNT3, FGF23 and
KLOTHO form part of a phosphate regulating pathway [26]. For
example, GALNT3 initiates a mucin type O-glycosylation and is
known to selectively O-glycosylate a furin-like convertase recog-
nition sequence in FGF23, which prevents proteolytic processing
of FGF23 and allows secretion of intact FGF23 [27]. Indeed,
patients with TC due to GALNT3 and FGF23 mutations have low
circulating concentrations of intact FGF23 [16]. FGF23 inhibits
the expression of the renal 25-hydroxyvitamin D-1a-hydroxylase
(Cyp27b1), thereby decreasing serum concentrations of 1,25-
dihydroxyvitamin D which results in a reduction of intestinal
phosphate absorption. In addition, FGF23 which requires the co-
receptor KLOTHO for bioactivity, downregulates the renal type
II sodium-phosphate co-transporters (NPT2a (Slc34a1) and
NPT2c (Slc34a3)) [28,29], thereby decreasing renal tubular
reabsorption of phosphate and leading to phosphaturia. In vivo
studies of phosphate homeostasis have been greatly advanced by
the availability of Fgf23 [30] and Kl [31] null mice. The availability
of a Galnt3 null mouse, which was not available at the
commencement of our study, would further facilitate investigations
of phosphate homeostasis, and we therefore pursued studies to
establish such a mouse model by assessing the progeny of mice
treated with the chemical mutagen N-ethyl-N-nitrosourea (ENU)
[32] for the occurrence of soft tissue (ectopic) calcification in
association with hyperphosphataemia.
Results
Phenotypic Identification of Tumoural Calcinosis (TCAL)
Mice
Plasma biochemical analysis, at 12 weeks of age, of 14 G3
progeny (10 males and 4 females) derived from matings between
parents and their offspring to yield autosomal recessive phenotypes
revealed three mice (2males and 1 female) to have plasma
phosphate concentrations of 3.53 mmol/l, 3.10 mmol/l and
2.87 mmol/l, which represented values that were .+3 standard
deviations (SD) above the mean plasma phosphate for matched
wild-type G3 other unrelated cohort controls (mean
6SD=1.9060.28 mmol/l, n = 80 (28 males and 52 females).
Radiography revealed these 3 mice to have widespread soft tissue
opacities (Fig. 2A). Thus, these mutant mice which had ectopic
calcification in association with hyperphosphataemia, displayed
phenotypic traits reminiscent of TC and the phenotype was
designated TCAL and the locus, Tcal. Dental and retinal
abnormalities were not identified in these TCAL mice. Breeding
of affected TCAL males (2 mice from the original G3 progeny and
2 newly bred affected G3 mice, aged 10–16 weeks) with 8 different
wild-type C3H females failed to yield any pregnancies, thereby
suggesting that the TCAL males were infertile. However, TCAL
female mice were fertile, and interbreeding of their progeny
confirmed that TCAL was inherited as an autosomal recessive
trait.
TCAL Mice have Ectopic Calcification, Testicular
Abnormalities and Increased Apoptosis
Von Kossa staining of tissues from the 3 TCAL affected G3
mice, described above, and 3 unaffected littermates (2 males and 1
female) revealed ectopic calcifications in subcutaneous tissues,
cutaneous striated muscle, heart, aorta, kidney, tongue (Fig. 2B)
and testicular artery (Fig. 2C) only in those sections from TCAL
mice. In addition, haematoxylin and eosin (H&E) staining of
TCAL mouse testes revealed disorganisation of the seminiferous
tubules with a marked reduction of Sertoli cells and spermatozoa
(Fig. 2C), consistent with a significant loss of germ cells and the
observed infertility of these male TCAL mice. Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining of testicular sections, revealed the TCAL male mice to
have increased apoptosis in the lumen and periphery of
seminiferous tubules, which likely involved spermatozoa, and
Sertoli cells or spermatocytes (Fig. 2D), respectively. In addition,
TUNEL staining of kidney sections revealed that TCAL male
mice had increased apoptosis involving the interstitial cells in the
renal medulla (Fig. 2E).
Figure 1. Schematic representation of GALNT3 structure. GALNT3 contains 3 domains which comprise a transmembrane domain (TMD) which
is formed by residues 20 to 37; a glycosyltransferase domain which is formed by residues 188 to 374; and a carbohydrate-binding domain which is
formed by residues 506 to 630, and contains two QXW repeats formed by residues 587–589 and 625–627, respectively. Human GALNT3 has four
potential N-linked glycosylation sites (shown as branches) at amino acid residues 132, 297, 484 and 619, respectively [61]; whereas mouse Galnt3 has
two potential N-linked glycosylation sites (not shown) at amino acid residues 297 and 484 (NetNGlyc 1.0). Twenty five GALNT3 mutations (10
missense, 6 nonsense and 9 frameshift/deletion) have been reported in patients with familial tumoural calcinosis (FTC) and hyperostosis-
hyperphosphataemia syndrome (HHS) (asterisked); and details of these 25 GALNT3 mutations are provided in Table 1. Four GALNT3 mutations
(Glu281Gly, Leu366Arg, Arg438Cys and 464–508 deletion) have been reported in patients with FTC and HHS (bold and asterisked), thereby indicating
that these 2 disorders are allelic variants [3,6,18,19,24]. The location of the ENU-induced mouse TCAL Trp589Arg mutation, which involved an
evolutionary conserved Trp (W) residue (Fig. 3D), within the carbohydrate-binding domain, is shown relative to GALNT3 mutations identified in man.
doi:10.1371/journal.pone.0043205.g001
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Mapping of the Tcal locus to Chromosome 2C1.3-C2 and
Identification of a Galnt3 Missense Mutation
Genome-wide mapping using DNA samples from 17 affected
TCAL G5 mice (10 males and 7 females) and 91 SNP sets localised
the Tcal locus to a 8.47 Mb region (between 62.64 and 71.11 Mb)
flanked by rs28002552 and rs4223216 on chromosome 2C1.3–C2
(Fig. 3A). This interval contained 95 genes, which included Galnt3
[2]. DNA sequence analysis of the Galnt3 gene revealed a T to A
transversion at codon 589 that resulted in a missense mutation
Trp589Arg (Fig. 3B). The mutation was confirmed using the
amplification refractory mutation system (ARMS) PCR method
[33]. Thus, PCR using wild-type (WT)-specific primers yielded
a 307 bp product only in DNA from unaffected mice (WT or
heterozygous (Tcal/+)), whereas mutant-specific primers yielded
a 230 bp product only in DNA from TCAL affected mice (Tcal/
Tcal) or unaffected heterozygotes (Tcal/+) (Fig. 3C). The
Trp589Arg mutation was found to involve an evolutionary
conserved Trp (W) residue (Fig. 3D) that is part of the first of
two QXW repeats within the carbohydrate-binding domain of
GALNT3 (Fig. 1).
Table 1. GALNT3 mutations identified in familial tumoural calcinosis (FTC) and hyperostosis-hyperphosphataemia syndrome (HHS)
patients.
No.a Mutationb Codon Predicted effectc Clinical disorderd References
Exon 1
1 c.T2A 1 p.Met1, loss of start codon HHS [17]
2 c.42_57 del 14 p.Arg14Ser fsX26 FTC [22]
3 c.C484T 162 p.Arg162X FTC [6,7]
4 c.G485A 162 p.Arg162Gln FTC [16]
Exon 2
5 c.516–2A.T R skip 173 p.Cys173Leu fs176 X FTC [5,7]
6 c.677delC 226 p.Ala226Val fs228X FTC [16]
Exon 3
7 c.803–804insC 269 p.Thr269Asn fs281X HSS [23]
8 c.C815A 272 p.Thr272Lys FTC [14]
Exon 4
9 c.G839A 280 p.Cys280Tyr HHS [17]
10 c.A842G 281 p.Glu281Gly FTC/HHS [3]
11 c.T966G 322 p.Tyr322X FTC [20]
Exon 5
12 c.C1076A 359 p.Thr359Lys FTC [14]
13 c.T1097G 366 p.Leu366Arg FTC/HHS [3]
14 c.1102–1103 insT 368 p.Ser368Phe fs371X FTC [8]
Exon 6
15 c.T1245A 415 p.His415Gln FTC [18]
16 c.G1313A 438 p.Arg438His HHS [15]
17 c.C1312T 438 p.Arg438Cys FTC/HHS [18,19]
18 c.A1387T 463 p.Arg463X FTC [21]
Exon 7
19 c.C1441T 481 p.Gln481X FTC [20]
20 c.G1460 A 487 p.Trp487X FTC [8]
21 c.1524+1G.AR skip exon7 464 Del 44aa at codons 464–508 FTC, HHS, FTC/HHS [6,24,25]
22 c.1524+5G.AR skip exon7 464 Del 44aa at codons 464–508 FTC [6]
Exon 8
23 c.1626+1G.AR skip exon8 509 Del 34aa at codons 509–542 HHS [23]
Exon 9
24 c.T1720G 574 p.Cys574Gly FTC [16]
25 c.C1774T 592 p.Gln592X FTC [9,19]
aThe locations of these mutations are illustrated in Figure 1.
bNucleic acid change at base pair in the cDNA sequence (Genbank accession number NM_004482.3); del, deletion; skip, exon skipping; and ins, insertion.
caa, amino acid; del, deletion; fs, frameshift. Mutations 2, 4, 5, 6, 14, 15, 16, 17, 18, 20, 21, 24 and 25 were identified as homozygotes. Of these, mutations 5, 14, 17, 21 and
25 were also identified in other patients as compound heterozygotes. Compound heterozygous mutations were identified in the following combinations: 1+9, 3+5,
3+21, 7+23, 8+12, 10+14, 11+19, and 17+25.
dFTC, familial tumoural calcinosis; HHS, hyperostosis-hyperphosphataemia syndrome.
doi:10.1371/journal.pone.0043205.t001
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In vitro and in vivo Functional Characterization of Mutant
Galnt3
To investigate the functional consequences of the Trp589Arg
Galnt3 mutation in vitro, WT and mutant enhanced green
fluorescent protein (EGFP)-tagged Galnt3 cDNA constructs were
transfected in COS-7 cells and their sub-cellular localization
assessed by immunofluorescence and confocal microscopy. WT
Galnt3-EGFP, which co-localized with the Golgi marker, GM130
(Fig. 4A), was found to be expressed in the Golgi apparatus,
whereas the expression pattern of the Arg589 mutant Galnt3
showed predominant co-localization with the endoplasmic re-
ticulum (ER) marker, protein disulphide isomerase (PDI) (Fig. 4A),
thereby suggesting impaired trafficking and ER retention of the
mutant protein. Further investigation of the in vivo functional
consequences of this Arg589 Galnt3 mutation revealed an effect
on glycosylation (Fig. 1 and 4B). Thus, incubation of kidney
homogenates from WT littermates, Tcal/+ and Tcal/Tcal mice in
the presence or absence of the deglycosylating enzyme PNGase F
and examination of the products by Western blot analysis using an
anti-GALNT3 antibody, revealed that the kidney homogenates
from both WT littermates and Tcal/+ G3 mice had three
processed Galnt3 products, one of which was undetectable upon
PNGase F digestion, thereby indicating that this was a glycosylated
product; in contrast, the kidney homogenate from Tcal/Tcal mice
lacked the glycosylated form of Galnt3, thereby indicating
a defective glycosylation of the mutant protein (Fig. 4B).
Plasma Biochemistry Analysis
Plasma was collected from adult G3–G5 mice (n = 68) from over
10 weeks of age and these consisted of 21 WT (+/+) littermates (10
males and 11 females), 29 Tcal/+ mice (13 males and 16 females),
and 18 Tcal/Tcal mice (7 males and 11 females). Tcal/Tcal mice,
but not Tcal/+ mice had significantly elevated plasma phosphate
concentrations (p,0.001) (Fig. 5A) and reduced plasma alkaline
phosphatase activity (p,0.05) (Fig. 5B) when compared to WT
littermates. The plasma calcium (Fig. 5C) and PTH concentrations
(Fig. 5D) were similar in the WT, Tcal/+ and Tcal/Tcal adult mice.
Tcal/Tcal adult mice, but not Tcal/+ adult mice, had significantly
reduced plasma concentrations of intact Fgf23 (p,0.01) (Fig. 5E),
but elevated circulating concentrations of 1,25-dihydroxyvitamin
D (p,0.05) (Figure 5F), when compared to WT littermates.
Assessment of Bone Structure by Micro-computed
Tomography
Dual-energy X-ray absorptiometry (DEXA) and microcom-
puted tomography (CT), was performed in 53 G3–G5 (31 males (8
WT littermates, 12 Tcal/+, 11 Tcal/Tcal) and 22 females (7 WT
littermates, 10 Tcal/+ and 5 Tcal/Tcal)) and 18 G5 (9males (4 WT
littermates and 5 Tcal/Tcal) and 9 females (4 WT littermates and
Tcal/Tcal)) adult mice, respectively, that were .12 weeks of age.
Areal bone mineral density (BMD), assessed using DEXA in
.12 week old mice, has been previously reported [34] to be
significantly elevated in Tcal/Tcal mice, but not Tcal/+mice, when
compared to WT littermates (mean BMD6SD: males
(WT=0.058060.0029 g/cm2, n = 8; Tcal/
+=0.061060.0062 g/cm2, n = 12; Tcal/
Tcal=0.066960.0053 g/cm2, n= 11, p,0.001) and females
(WT=0.056560.0028 g/cm2, n = 7; Tcal/
+=0.057260.0041 g/cm2, n = 10; Tcal/
Tcal=0.063360.0027 g/cm2, n= 5) p,0.001). We therefore
further assessed bone structure by micro CT, in Tcal/Tcal mice
and WT littermates (Fig. 6A), but not Tcal/+ mice, as their areal
BMD was previously reported to be similar to that of WT
littermates [34]. Micro-CT analysis of tibiae (Fig. 6A) revealed that
cortical bone volume was significantly increased in male and
female Tcal/Tcal mice. In addition, trabecular number was
increased, and the structural model index decreased in male
Tcal/Tcal mice (Table 2). Finally, cross-sectional analysis revealed
the presence of calcinosis in soft tissues adjacent to the knee
(Fig. 6B), elbow (not shown) and shoulder (not shown) in Tcal/Tcal
mice but not WT littermates.
Effects of Galnt3 Mutation on Gene Expression in Bone
and Kidney
Femora and kidneys were obtained from 3 WT littermates (2
males and 1 female) and 3 Tcal/Tcal (2 males and 1 female) adult
G5 mice that were .18 weeks of age. RNA was extracted and
gene expression investigated by quantitative reverse transcriptase-
PCR (qRT-PCR). Tcal/+ mice were not studied, as plasma
biochemistry (Fig. 5) and areal BMD [34] analysis had not
revealed any significant differences when compared to WT
littermates. Data from Tcal/Tcal male and female mice were
combined as analysis of plasma biochemistry (Fig. 5) and areal
BMD [34] had revealed similar abnormalities when compared to
WT littermates. The expression of Galnt3 and Fgf23 was studied in
femora, and this revealed that Tcal/Tcal mice had significantly
increased expressions of Galnt3 (Fig. 7A) and Fgf23 (Fig. 7B) by 1.8-
fold and 19-fold, respectively, when compared to that in WT
littermates. The higher Fgf23 expression contrasts with the lower
circulating concentrations of Fgf23, suggesting that there is a loss
of negative feedback in the Tcal/Tcal mice (Fig. 5E). The effects of
the reduced circulating concentrations of Fgf23 on the renal
expression of Klotho (Kl) [26] (Fig. 7C), vitamin D 1-alpha
hydroxylase (Cyp27b1) (Fig. 7D) and the renal sodium-phosphate
co-transporters (Npt2a) [28] (Fig. 7E) and Npt2c [29] (Fig. 7F), were
investigated; however, these were found to be similar in Tcal/Tcal
mice and WT littermates. Thus, the observed plasma biochemical
abnormalities in phosphate (Fig. 5A and 5B) and 1,25-dihydrox-
yvitamin D (Fig. 5F) homeostasis, could not be attributed to any
possible effects of reduced plasma Fgf23 concentrations on renal
expression of Npt2a, Npt2c, and Kl; or Cyp27b1, respectively.
Discussion
Our study describes a mouse model (TCAL) with an ENU-
induced Galnt3 mutation that has similarities to familial
tumoural calcinosis (FTC) in man (Table 3). Thus, TCAL mice
had hyperphosphataemia in association with ectopic calcifica-
tion. Moreover, TCAL mice had increased circulating concen-
trations of 1,25-dihydroxyvitamin D, and decreased plasma
intact Fgf23 concentrations. TCAL was inherited as an
Figure 2. Phenotypic features of TCAL mice. (A) Radiography of an adult (12 week old) TCAL male mouse revealed widespread subcutaneous
soft tissue opacities (white arrows); two magnified areas (a and b) are shown to illustrate detailed views. (B) Von Kossa stained sections from TCAL
male mouse (36 week old) showing ectopic calcification in skin (arrow indicates mineralised panniculus fat), cutaneous striated muscle, heart, aorta,
kidney and tongue submucosa. (C) Analysis of testes. Calcification was observed in the testicular arteries (left panel, von Kossa staining), and H&E
sections (middle and right panels) of wild type (WT) and TCAL testis revealed disorganised seminiferous tubules and loss of spermatozoa in TCAL
mice. (D and E) TUNEL staining of WT and TCAL testis and kidney sections, respectively, revealed increased apoptosis (green staining) in the tissues of
TCAL mice.
doi:10.1371/journal.pone.0043205.g002
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autosomal recessive disorder, consistent with the inheritance of
FTC, and due to a missense Trp589Arg Galnt3 mutation
(Fig. 3B and 3C) that was induced by ENU, which is known to
induce multiple mutations simultaneously [32]. However, the
likelihood that another genetic defect within the 8.47 Mb region
that was established to be the location of the Tcal locus (Fig. 3A),
could be the underlying cause of TCAL is ,0.01, based on the
following reasoning. The nominal ENU induced base pair
mutation rate for potentially functional mutations has been
estimated to be 1 in 1.82 Mb of coding DNA in the F1 founder
animals [35] and given that ,2.5% of the mouse genome is
coding, it has been calculated that the probability of two
functional mutations arising within a 5 Mb genomic region is
,0.002 [36]; thus, the likelihood of the Galnt3 Trp589Arg and
another functional mutation arising within the 8.47 Mb contain-
ing the Tcal locus is ,0.004. This indicates that the Galnt3
Trp589Arg mutation, which was shown also to result in ER
retention of the mutant protein (Fig. 4A), as well as defective
glycosylation (Fig. 4B), is highly likely to be the sole genetic
defect causing TCAL. Although the Trp589Arg missense Galnt3
mutation associated with TCAL in the mouse has not been
identified in patients with FTC, it is important to note that
Trp589 is conserved in both species and that the Trp589Arg
mutation is representative of 40% of GALNT3 abnormalities
which are also missense mutations in patients with FTC and
HHS [3,14–19].
During the course of our study, a Galnt3-deficient mouse was
reported [31], and this mouse model and TCAL had some
phenotypic features in common (Table 3). Thus, TCAL and
Galnt3-deficient mice are characterized by the presence of
hyperphosphataemia, decreased plasma alkaline phosphatase
activity, reduced circulating intact Fgf23, increased Fgf23 gene
expression in bone, increased whole body BMD in male mice, and
male infertility due to loss of spermatozoa in seminiferous tubules.
However, there are also important differences between TCAL and
the Galnt3-deficient mice (Table 3) and these include: an absence
of growth retardation in TCAL mice; elevated plasma 1,25-
dihydroxyvitamin D concentrations in TCAL mice (Fig. 5F);
normal plasma concentrations of calcium and PTH in TCAL
mice; increased areal BMD in female TCAL mice; and ectopic
calcification (Figs. 2A & 2B) in TCAL mice, which is a hallmark of
FTC in man [4], but was notably absent in Galnt3-deficient adult
mice, even when aged to 1 year [31]. The basis of these differences
between TCAL and Galnt3-deficient mice remains to be elucidat-
ed. A possible explanation may involve strain-specific differences
as the TCAL mice were on a mixed C57BL/6J and C3H
background, whilst the Galnt3-deficient mice were on a C57BL/6J
and 129SvEv background [31]. In addition, ENU-induced mouse
models have been reported to differ in phenotypic features when
compared to the corresponding null mice, generated using
targeted gene ablation strategies [32]. For example, mice deficient
for the fat mass and obesity associated (FTO) gene (FTO2/2) have
been reported to have phenotypic differences when compared to
mice that were homozygous for the ENU hypomorphic mutant
FTOI367F. Thus, FTO2/2 and FTOI367F mice both have reduction
in adiposity and weight, but only FTO2/2 mice show perinatal
lethality, and age-related reduction in size and length [37].
Another possibility that may contribute to these differences in
severity of the phenotype may be related to the functions of other
GALNTs, e.g. Galnt6 that can partially compensate for the loss of
Galnt3 [31]. However, it is also important to note that there is
significant variability in the clinical manifestations amongst FTC
patients (Table 3). For example, FTC, in man, has a variable age
of onset with variation in the severity of calcified lesions, such that
some patients suffer from large extra-skeletal lesions that require
surgery [4,38], whilst others have mild disease that may be
asymptomatic [14]. In addition, GALNT3 mutations in man, may
result in the hyperostosis-hyperphosphatemia syndrome, (HHS)
[15,17,23,24], in which cortical hyperostosis is a notable feature.
However, the same GALNT3 mutation may be associated with
FTC and HHS in members of the same family or in unrelated
families [6,18,19,24]. Indeed, FTC and HHS are considered to be
allelic variants and the situation between TCAL and Galnt3-
deficient mice may be analogous. Thus, TCAL mice had ectopic
calcifications (Fig. 2) and thickening of cortical bone (Table 2),
consistent with FTC and HHS, whilst Galnt3-deficient mice did
not have soft tissue calcification, but only had thickening of cortical
bone, consistent with isolated HHS.
The three most notable differences between human FTC and
mouse TCAL are the findings of decreased plasma alkaline
phosphatase activity, and male infertility in TCAL mice which are
not found in man, and the occurrence of smaller tumoural
calcinosis lesions in TCAL mice. Interestingly, the Galnt3-deficient
mouse also was reported to have these differences, and the basis of
these inter-species phenotypic differences remains to be elucidated.
The observation of decreased plasma alkaline phosphatase activity
has in the Galnt3-deficient mice been attributed to be associated
with the reported increased bone mineralization in these mutant
mice [31]. Given the reported increased BMD [34] (Table 3) in
the Tcal/Tcal mice, it would seem probable that the decreased
plasma alkaline phosphatase activity in the Tcal/Tcal mice is also
a reflection of increased bone mineralization. Tcal/Tcal and
Galnt3-deficient male mice had infertility, and it is important to
note that recent studies indicate that this is not due to the
hyperphosphataemia, as normalizing the serum phosphate con-
centrations in Galnt3-deficient mice, by use of a low phosphate diet
failed to correct the infertility [39]. Infertility in males with FTC or
HHS is not a notable feature. However, one boy with FTC, has
been reported to have testicular microlithiasis which was
associated with oligoazoospermia, and histology revealed that
the calcifications were localized to the lumen of the seminiferous
tubules and the interstitium [21]. The FTC in this boy and his
family did not co-segregate with an autoimmune disorder, which
resulted in arthralgia, vasculitis and chronic immune thrombocy-
topenic purpura, thereby indicating that the oligoazoospermia was
not due to the autoimmunity [21]. GALNT3 is highly expressed in
the testis, and its loss may cause deposition of calcium in the testis;
indeed, it has been suggested that testicular calcification may be an
Figure 3. Mapping of Tcal locus and identification of Galnt3 mutation. (A)The Tcal locus, which originated in a C57BL/6 ENU-mutagenised
male and is hence inherited with the C57BL/6 alleles, was mapped to a 8.47 Mb region flanked by the SNPs rs28002552 and rs4223216 on
chromosome 2C1.3–C2. This region contained 95 genes which included the Galnt3 gene. (B) DNA sequence analysis of Galnt3 identified a T to A
transversion in codon 589, such that the wild type (WT) sequence, TGG which encodes an evolutionarily conserved tryptophan (Trp) residue was
altered to the mutant (m) sequence, AGG which encodes an arginine (Arg) residue. (C) Amplification refractory mutation system (ARMS) PCR was
used to confirm the presence of the mutation by designing primers (n, normal (WT) and m, mutant) that yielded 307 bp WT and 230 bp mutant PCR
products, respectively. PCR amplification of Gapdh was used as a control for the presence of DNA. N =numbers of mice with each genotype. (D)
Protein sequence alignment (CLUSTALW) of Galnt3 from 5 species revealed that the Trp (W) residue is evolutionarily conserved in the Galnt3
orthologues of mouse, human, monkey, xenopus and zebrafish.
doi:10.1371/journal.pone.0043205.g003
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Figure 4. Mislocalization and defective glycosylation of mutant Galnt3. (A) COS-7 cells were transiently transfected with either EGFP-wild-
type, WT (Trp589), or EGFP-mutant (Arg589) constructs, and counterstained with anti-GM130 antibody, which immunostains the Golgi apparatus
(red), or anti-PDI antibody, which immunostains the ER (red). DAPI was used to stain the nucleus (blue). WT Galnt3 co-localizes with GM130, but not
PDI (data not shown), thereby revealing that it is targeted to the Golgi apparatus. However, the mutant Galnt3 co-localizes with PDI and is
predominantly found in the ER. (B) Western blot analysis of kidney homogenates using anti-GALNT3 antibody, revealed that protein lysates from WT
littermates, and Tcal/+ mice had three immunoreactive products (a, b and c) whereas those from Tcal/Tcal mice had only two products (b and c).
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underestimated feature of FTC [21]. The differences in the sizes of
the calcinosis lesions between human FTC and the Tcal/Tcal and
Galnt3-deficient mouse models, may in part be attributed to the
observed variability of FTC lesions in man [4,14,38]. However,
they may also be related to dietary phosphate intake. For example,
Galnt3-deficient mice when placed on diets containing either 0.1%
PNGase F treatment resulted in loss of the largest Galnt3 product (band a) observed in the lysates from WT littermates, and Tcal/+ mice, indicating
that these were glycosylated products.
doi:10.1371/journal.pone.0043205.g004
Figure 5. Plasma biochemical analyses. Plasma from WT littermates (+/+) (black), Tcal/+ (grey) and Tcal/Tcal (white) adult mice, aged 10 weeks
was obtained and used to measure plasma concentrations of (A) phosphate, (B) alkaline phosphatase (ALP) activity, (C) calcium (adjusted for albumin
concentrations), (D) PTH, (E) intact Fgf23, and (F) 1,25-dihydroxyvitamin D. Tcal/Tcal mice but not Tcal/+ mice, had: hyperphosphataemia, reduced
alkaline phosphatase activity, reduced plasma concentrations of intact Fgf23, and elevated circulating concentrations of 1,25-dihydroxyvitamin D. The
plasma concentrations of calcium and PTH were not significantly different. Sufficient volumes of plasma samples from female mice were not available
for an analysis of 1,25-dihydroxyvitamin D concentrations; however, analysis of pooled samples from 2 WT female littermates, 3 Tcal/+ females, and 3
Tcal/Tcal females revealed that the plasma 1,25-dihydroxyvitamin D concentrations were 58.2 pmol/l, 55.7 pmol/l, and 71.7 pmol/l, respectively.
These results indicate that the plasma 1,25-dihydroxyvitamin D concentrations in WT littermates and Tcal/+ females are similar, but are elevated in
Tcal/Tcal females, and are consistent with the observations in male mice. The data are represented as mean 6 SEM, and p-values are from unpaired
Students t-test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0043205.g005
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(low), 0.3% (low normal), 0.6% (normal) or 1.65% (high)
phosphate developed a significant increase in serum calcium
concentrations when on the high-phosphate diet [39], although
Galnt3-deficient mice, aged to 1 year, have not been observed to
develop ectopic calcification when on a 0.93% phosphate diet
[31]. It has been postulated that the hypercalcaemia induced by
Figure 6. Micro-CT analysis. (A) Cross sections of proximal tibia from male and female mice revealed an increase in cortical bone volume in Tcal/
Tcalmice (aged 12 weeks) when compared to WT littermates. (B) Three dimensional views of tibiae revealing ectopic calcification (arrowed) in a Tcal/
Tcal male mouse (aged 12 weeks).
doi:10.1371/journal.pone.0043205.g006
Table 2. Bone volume, assessed by micro-CT of tibiae, from 12 week old mice.
Males Females
WT (+/+) (n = 4) Tcal/Tcal (n = 5) WT (+/+) (n = 4) Tcal/Tcal (n =5)
BV/TV (%) 10.361.3 17.763.0 14.462.4 18.861.1
Tb. Th (mmx1022) 4.260.05 4.060.1 5.160.2 5.460.2
Tb. N (mm21) 2.460.3 4.460.7* 3.360.7 1.960.3
SMI 1.660.2 0.760.1** 1.560.3 1.160.3
C. BV (mm3) 0.9860.03 1.1660.04** 0.8960.08 1.1660.04*
WT (+/+), refers to wild-type littermates; BV/TV = trabecular bone volume (BV) fraction as a proportion of total volume (TV) of organ; Tb. Th = trabecular thickness, Tb.
N = trabecular number; SMI = structural model index; and C.BV = cortical bone volume. Values represent means 6 SEM; Unpaired student’s t-test: *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0043205.t002
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the 1.65% (high) phosphate diet may likely contribute to the
overall increase in calcium-phosphate products and subsequently
ectopic calcifications. Thus, it seems possible that the variability in
the size of the tumoural calcinosis lesions in man, may be related
to dietary phosphate, with high intake being associated with the
larger lesions. Another possibility that may contribute to the
variability in the size of the tumoural calcinosis lesions, may
involve a response to injury. For example, it has been suggested
that early calcinosis lesions are triggered by injury and bleeding,
with subsequent aggregation of foamy histiocytes, which become
transformed into cystic cavities lined by osteoclast-like giant cells,
and surrounded by monocytes and iron-loaded macrophages
[40,41]. Studies investigating the responses to injury and the
underlying inflammatory and immune mechanisms in the Tcal/
Tcal mice, which have calcinosis lesions, and in the Galnt3-deficient
mice, which do not have calcinosis lesions (Table 3), may help to
elucidate the basis of these differences.
GALNT3 belongs to a large family of Golgi-resident glycosyl-
transferases that initiate mucin-type O-glycosylation, one of the
most abundant forms of protein glycosylation found in eukaryotic
cells [42,43]. Structurally, GALNT3 consists of an N-terminal
transmembrane domain, a central catalytic (glycosyltransferase)
domain and a C-terminal ricin (carbohydrate binding) domain
(Fig. 1). FTC and HHS mutations are distributed throughout the
GALNT3 gene, with no evidence for clustering. The Trp589Arg
missense mutation identified in TCAL mice is situated in the
carbohydrate binding domain (Fig. 1) which is characterized by
the presence of QXW (glutamine-any amino acid-tryptophan)
repeats [44], and two of these which are present in both human
and mouse GALNT3 orthologues. The Trp589Arg mutation in
TCAL mice alters the tryptophan residue in the first repeat. Each
Figure 7. Analysis of gene expression in bone and kidneys. RNA from femora and kidneys was extracted from WT littermates (black) (2 males
and 1 female) and Tcal/Tcal (white) (2 males and 1 female) adult mice, aged 18–20 weeks. Quantitative reverse transcriptase-PCR (qRT-PCR) was used
to study the expression of: (A) Galnt3 and (B) Fgf23 in femora; and (C) Kl, (D) Cyp27b1, (E) Slc34a1, and (F) Slc34a3 in kidneys. Samples were analysed
in triplicate (n = 3 mice for each group i.e. total of 9 samples) and mRNA levels were normalized to Gapdh and expressed as fold change (mean 6
SEM) compared to WT. The data from males and females were combined, as differences in plasma biochemical analysis between the genders had not
been observed (Fig. 5). The expression of Galnt3 and Fgf23 was significantly increased in the bone of Tcal/Tcal mice when compared to that of WT
littermates; however, the expression of the renal expressed genes Kl, Cyp27b1, Slc34a1 and Slc34a3 was not significantly different in the Tcal/Tcalmice
compared to WT littermates. P-values are from unpaired Students t-test (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0043205.g007
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QXW repeat forms an omega loop and it has been suggested that
these could be important for post-translational protein folding and
stabilization, and for carbohydrate binding [44]. Indeed, our
in vitro and in vivo studies of the Galnt3 Trp589Arg mutant, which
alters the tryptophan in the first QXW repeat, demonstrated such
roles for the QXW repeats by showing impaired trafficking of the
mutant protein, with its retention in the endoplasmic reticulum
(Fig. 4A) and defective glycosylation of the mutant Galnt3 protein
in kidney lysates from Tcal/Tcal mice, respectively (Fig. 4B).
Studies of null mouse models of FGF23 [30], vitamin D-1-alpha
hydroxylase [45], klotho [46] and NPT2a [28] have established that
FGF23 reduces serum phosphate levels by suppressing phosphate
reabsorption in proximal kidney tubules [47], thereby playing a key
role as a regulator of phosphate metabolism. FGF23 is O-
glycosylated by GALNT3 to protect it from proteolytic cleavage
[10,48], and the underlying molecular mechanism causing FTC
and HHS in patients with GALNT3 mutations involves defective
glycosylation of FGF23 resulting in enhanced cleavage and
inactivation of FGF23 [47]. Our results, which reveal a reduction
in circulating concentrations of intact full-length Fgf23 in Tcal/
Tcal mice, indicate that the Trp589Arg Galnt3 mutation is an
inactivating mutation whose loss-of-function releases the inhibition
on 1,25-dihydroxyvitamin D synthesis [49], as observed by
increased plasma concentrations of 1,25-dihydroxyvitamin D.
Furthermore, our in vivo results which show a 1.8 fold increase in
bone expression of Galnt3 in Tcal/Tcal mice in response to chronic
hyperphosphataemia are in agreement with in vitro studies which
showed that GALNT3 gene expression can be induced by
administration of extracellular phosphate to cultured human
fibroblasts [50]. Moreover, our analysis, which revealed extensive
apoptosis in testis (Fig. 2D) and kidney (Fig. 2E) in association with
the prevailing hyperphosphataemia in Tcal/Tcal mice, is in
agreement with in vitro studies that have reported that high levels
of extracellular phosphate are a potent inducer of oxidative stress
and apoptosis in cultured human endothelial cells [51] and
osteoblast-like cells from human bone explants [52].
In summary, our study has identified a mouse model for
autosomal recessive FTC due to an ENU-induced missense
mutation (Trp589Arg) in Galnt3 and this will help to elucidate
further the molecular mechanisms of FTC and provide a model
for investigating novel treatments.
Materials and Methods
Ethics Statement
All animal studies were carried out using guidelines issued by
the Medical Research Council in ‘Responsibility in the Use of
Animals for Medical Research’ (July 1993) and Home Office
Project License Number 30/2433. Experiments were approved by
the Medical Research Council Harwell ethics committee.
Generation of Mutant Mice
Male C57BL/6J mice were treated with ENU and mated with
untreated C3H female mice [32]. The male progeny (G1) were
subsequently mated with normal C3H females to generate G2
progeny. The female G2 progeny were backcrossed to the G1
fathers and the resulting G3 progeny [32] were screened at
12 weeks of age for recessive phenotypes. Mice were fed an
expanded rat and mouse no. 3 breeding diet (Special Diets
Services, Witham, UK) containing 1.15% calcium, 0.82%
phosphate and 4088.65 units/kg vitamin D, and given water ad
libitum. Wild-type littermates were used as controls, as these
would have similar random assortments of segregating C57BL/6J
Table 3. Comparison of Galnt3-deficient and TCAL mouse models with FTC and HHS in man.
Main characteristics Galnt32/2 micea Tcal/Tcal miceb FTC in manc HHS in mand
Derivation of mutation KO ENU SN SN
Ectopic calcification 2 + + 2
Growth retardation in males + 2 2 2
Infertility in males + + ? ?
Hyperphosphataemia + + + +
Plasma alkaline phosphatase activity Q Q N/q N
Plasma calcium concentration q N N N
Circulating PTH Q N N N
Circulating1,25-dihydroxyvitamin D N q N/q N/q
Reduced circulating intact Fgf23 + + + +
Increased areal BMD +, in males only +, males and females* ? ?
Apoptosis in testis and kidney ? + ? ?
Fgf23 expression in bone q q ? ?
Galnt3 expression in bone ? q ? ?
NPT2a expression in kidney q N ? ?
Kl expression in kidney q N ? ?
KO, knockout model; ENU, N-ethyl-N-nitrosourea induced model; SN, spontaneous naturally occurring.
+, present; 2, absent; N, normal; Q, reduced; q, increased; ?, not reported.
*Previously reported (reference [34]).
apreviously reported (reference [31]);
bthis study;
cpreviously reported (references [3,5–9,14,16,18–22,24]);
dpreviously reported (references [3,15,17,19,23–25]).
doi:10.1371/journal.pone.0043205.t003
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and C3H alleles, to those of the mutant mice, thereby minimising
any strain-specific influences.
Plasma Biochemistry
Blood samples were collected from the lateral tail vein of mice
[53] that had fasted for 4 hours. Plasma samples were analysed for
total calcium, inorganic phosphate, alkaline phosphatase activity,
urea, creatinine and albumin on a Beckman Coulter AU680 semi-
automated clinical chemistry analyzer using the manufacturer’s
instructions, parameter settings and reagents, as described [53].
Plasma calcium was adjusted for variations in albumin concentra-
tions using the formula: ((albumin-mean albumin) 60.02) +
calcium), as described [54]. For analysis of PTH, FGF-23, and
1,25-dihydroxyvitamin D, blood samples were collected from the
retro-orbital sinus after terminal anaesthesia, and plasma was
separated by centrifugation at 3000 g for 5 min at 4uC. PTH was
quantified using a two-site ELISA kit (Immunotopics, California,
USA), intact FGF-23 was quantified using a two-site ELISA kit
(Kainos Laboratoties, Tokyo, Japan), and 1,25-dihydroxy vitamin
D was measured using an assay system (Immunodiagnostic
Systems, Boldon, UK) involving purification by immunoextraction
followed by quantification by enzyme immunoassay.
Imaging by Radiography and Micro-CT Scanning
Anaesthetised mice were subjected to digital radiography at
26 kV for 3 seconds using a Faxitron MX-20 digital X-ray system
(Faxitron X-ray Corporation, Lincolnshire, USA) [55]. Images
were processed using the DicomWorks software (http://www.
dicomworks.com/). For micro-CT scanning, formalin-fixed, un-
decalcified tibiae were used and analysed by a micro-CT scanner
(model 1172a, Skyscan) at 50 kV and 200 mA utilizing a 0.5
aluminium filter and a detection pixel size of 17.4 mm2. The
proximal tibia was scanned to measure trabecular bone [56], using
a detection pixel size of 4.3 mm2, and images were scanned every
0.7u through a 180u rotation. Scanned images were reconstructed
using Skyscan NRecon software and analyzed using the Skyscan
CT analysis software (CT Analyser v1.8.1.4, Skycan). A volume of
1 mm3 of trabecular bone 0.2 mm from the growth plate was
chosen. Trabecular bone volume as proportion of tissue volume
(BV/TV, %), trabecular thickness (Tb.Th, mmx1022), trabecular
number (Tb. N, mm21) and structure model index (SMI) were
assessed in this region using the CT analysis software.
Histology and Immunohistochemistry
Dissected tissues were fixed in 10% formalin, decalcified in
formical-4TM (Decal Chemical Corporation) for 3 days before
embedding in paraffin wax [55]. Sections (3–4 mm) were stained
with haematoxylin and eosin (H&E), and von Kossa, for
microscopy studies (Leica microscope model DM4000B, Leica
Microsystems, Milton Keynes, UK) and images captured (QIma-
ging camera model 10-RET-OEM-F-CLR-12, QImaging, Ca-
nada) [55]. TUNEL staining was performed on sections using the
ApopTag Fluorescein In Situ Apoptosis Detection kit (Millipore)
[57]. Stained sections were mounted in VECTASHIELDH
mounting medium containing 49,6-diamidino-2-phenylindole
(DAPI) (Vector laboratories, Peterborough, UK) to detect nuclei
[57].
Mapping, DNA Sequence Analysis and Genotyping
Genomic DNA was extracted from tail or auricular biopsies, as
described [53]. For genome-wide mapping, genomic DNA was
amplified by PCR using a panel of 91 single nucleotide poly-
morphic (SNP) loci arranged in chromosome sets, and the
products were analysed by pyrosequencing [55]. Individual exons
of Galnt3 were amplified from genomic DNA by PCR using gene-
specific primers and Taq PCR Mastermix (Qiagen, Crawley, UK),
and the PCR products sequenced using BigDye terminator
reagents and ABI 3100 sequencer (Life Technologies, Carlsbad,
USA). For genotyping, DNA was amplified by ARMS PCR using
Taq PCR Mastermix (Qiagen, Crawley, UK) and specific primers
for the wild-type (F: GACCATCGCCCCTGGAGAACAGA-
CAT, R: AGAAGTTTTTCACCTACAGAAGCCAAGCGT)
and mutant (F: CTTGTTTTATTTTGCAACTGGGCACAC,
R: GAGCCAATCACCTTCCGAATCTCTCT) Galnt3 se-
quences, and Glyceraldehyde 3-phosphate dehydrogenase (Gapdh)
(F: CTCAGCTCCCCTGTTTCTTG, R: GGAAAGCT-
GAAGGTGACGG), and separated by agarose gel electrophoresis
before image acquisition using a Gel DocTM UV transilluminator
(Bio-Rad, Hemel Hempstead, UK) [33].
In vitro and in vivo Expression Studies of Wild-type and
Mutant Galnt3
A full length mouse wild-type Galnt3 cDNA was amplified from
an IMAGE clone (IMAGE: 5342768) with Pfu Ultra II fusion
(Agilent Technologies, Stockport, UK) using the forward primer
(59- CTCAAGCTTGACAGAATGGCTCACCTTAAGC -39)
and the reverse primer (59- AGTGGATCCGA AT-
CATTTTGGCTAAAAATCCATT -39), and the PCR product
sub-cloned into pEGFP-N1 (Clontech, Saint-Germain-en-Laye,
France) [58]. The Galnt3 mutation was introduced using site-
directed mutagenesis with the forward primer 59-GGAGAACA-
GATAAGGGAGATTCGGA-39 and its reverse complement, and
sequence analysis of the constructs was undertaken using pre-
viously reported methods [58]. The wild-type and mutant Galnt3
constructs were transiently transfected into COS-7 cells using
FuGENE 6 reagent (Roche, Welwyn Garden City, UK) and 1 mg
of each construct as previously described [59] and expression
visualized by immunofluorescence [60]. Briefly, transfected cells
cultured on glass coverslips were fixed, permeabilized, blocked and
incubated with either mouse anti-Golgi matrix protein (GM130)
(BD Bioscience, Oxford, UK) or mouse anti-protein disulphide
isomerase (PDI) (Enzo Life Science, Exeter, UK) diluted 1:500.
The secondary antibody was AlexaFluor 594 goat anti-mouse
(Invitrogen, Paisley, UK) diluted 1:500. Coverslips were mounted
onto slides in VECTASHIELDH mounting medium with DAPI
(Vector laboratories, Peterborough, UK) and visualized by
confocal microscopy using a Leica TCS SP5 confocal system,
attached to a DMI 6000 microscope. Western blot analysis was
performed using equal amounts of proteins from kidney homo-
genates that were pre-incubated for 1 h at 37uC in the presence or
absence of peptide: N-glycosidase F (PNGase F), mixed with LDS
sample buffer (Invitrogen, Paisley, UK) before separation by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and electroblotting onto nitrocellulose membrane (Schlei-
cher and Schuell, Dassel, Germany) [60]. Membranes were
probed with the rabbit polyclonal anti-human GALNT3 antibody
(Sigma-Aldrich, Dorset, UK) followed by HRP-conjugated anti-
rabbit IgG (Bio-Rad, Hemel Hempstead, UK) and ECL detection
(GE Healthcare, Little Chalfont, UK). The membrane was
stripped and re-probed with HRP-conjugated mouse anti-
GAPDH antibody (Abcam, Cambridge, UK) as a loading control
[55].
In vivo Gene Expression Studies
Total RNA was isolated from kidneys using the RNeasy mini kit
(Qiagen, Crawley, UK). For extraction from bones, femora were
pulverised under liquid nitrogen, homogenised in QIAzol lysis
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reagent (Qiagen, Crawley, UK), mixed with chloroform and
centrifuged at 12000 g for 15 min and 4uC. RNA was extracted
from the upper aqueous phase using the RNeasy mini kit (Qiagen,
Crawley, UK). Two micrograms of RNA was used to synthesize
cDNA using AffinityScript multiple temperature reverse transcrip-
tase (Agilent Technologies, Edinburgh, UK) according to the
manufacturer’s instructions. cDNA templates were amplified by
quantitative PCR using SYBR Green (Applied Biosystems,
California, USA) and Applied BiosystemsH 7500 Fast Real-Time
PCR System [37], and gene-specific primers for Fgf23(F:
CCACGGCAACATTTTTGGA, R: CTGGCGGAACTTG-
CAATTCT), Galnt3 (F: TTCTCTGCACCGGGACCTT, R:
GGCGGGCAGCGCTTA), Klotho
(F:GGCTTTCCTCCTTTACCTGAAAA, R: CACATCCCA-
CAGATAGACATTCG ), Cyp27b1 (F: TGGAGTGGACACGG-
TATCCA, R: GGTCCCAGCTGTGATCTCAGA), NPT2a (F:
CTCCTCCGGCTTGTTGGA, R: GACAGAGGTTCC-
GATGTTGGA), NPT2c (F: TTGCTTCAGAGCAG-
TAGTGTCTTCA, R: CCCCAACCCCCATGAGA) and Gapdh
(F: AGCGAGACCCCACTAACATC, R: GGTTCACACC-
CATCACAAAC). Gene expression was assessed by SYBR green
detection, normalized to expression of Gapdh and analyzed by the
Comparative DDCT method to determine the difference in
mutants relative to wild-type groups [37].
Statistical Analysis
Mean values and standard deviations (SD) or standard errors of
mean (SEM) were calculated and analysis performed using
unpaired Student’s t-test for independent samples in which the
Bonferroni correction for multiple testing was applied [54]. P
values ,0.05 were considered significant.
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